ENDOLOGIX INC's ticker is and the CUSIP is 29266SAA4.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $141,000 | -0.7% | 144,000 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $142,000 | +42.0% | 144,000 | +38.5% | 0.00% | +100.0% |
| Q1 2018 | $100,000 | -1.0% | 104,000 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $101,000 | -96.8% | 104,000 | -96.8% | 0.00% | -97.9% |
| Q3 2016 | $3,117,000 | -62.3% | 3,230,000 | -64.0% | 0.05% | -62.4% |
| Q2 2016 | $8,263,000 | +25.8% | 8,967,000 | 0.0% | 0.12% | -33.2% |
| Q1 2016 | $6,570,000 | -12.6% | 8,967,000 | 0.0% | 0.19% | +15.4% |
| Q4 2015 | $7,519,000 | -4.9% | 8,967,000 | +2.1% | 0.16% | -13.4% |
| Q3 2015 | $7,903,000 | -8.2% | 8,786,000 | 0.0% | 0.19% | -4.1% |
| Q2 2015 | $8,607,000 | -3.2% | 8,786,000 | +0.1% | 0.20% | +10.2% |
| Q1 2015 | $8,894,000 | +3.2% | 8,780,000 | 0.0% | 0.18% | +5.4% |
| Q4 2014 | $8,619,000 | +12.0% | 8,780,000 | +1.8% | 0.17% | +4.3% |
| Q3 2014 | $7,694,000 | -12.1% | 8,625,000 | 0.0% | 0.16% | -16.1% |
| Q2 2014 | $8,757,000 | +5.7% | 8,625,000 | 0.0% | 0.19% | +8.5% |
| Q1 2014 | $8,282,000 | – | 8,625,000 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 51,117,000 | $46,140,000 | 1.90% |
| PFM Health Sciences, LP | 6,445,000 | $5,809,000 | 0.16% |
| Partner Investment Management, L.P. | 84,000 | $76,000 | 0.10% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 5,562,000 | $5,013,000 | 0.09% |
| OAKTREE CAPITAL MANAGEMENT LP | 6,000,000 | $5,423,000 | 0.08% |
| PALISADE CAPITAL MANAGEMENT, LP | 1,095,000 | $1,004,000 | 0.04% |
| ACUTA CAPITAL PARTNERS, LLC | 96,000 | $86,000 | 0.03% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,500,000 | $1,352,000,000 | 0.03% |
| AMUNDI ASSET MANAGEMENT US, INC. | 7,305,000 | $6,557,000 | 0.02% |
| Citadel Advisors | 6,230,000 | $5,624,000 | 0.01% |